Tilray Brands (NASDAQ:TLRY) Stock Price Down 11.8% on Insider Selling

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) dropped 11.8% during trading on Thursday after an insider sold shares in the company. The company traded as low as $6.82 and last traded at $6.94. Approximately 42,291,145 shares changed hands during mid-day trading, an increase of 852% from the average daily volume of 4,444,306 shares. The stock had previously closed at $7.87.

Specifically, Director David G. Hopkinson sold 33,556 shares of Tilray Brands stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total transaction of $232,878.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analyst Upgrades and Downgrades

TLRY has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. ATB Cormark Capital Markets dropped their price target on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a report on Thursday, April 2nd. Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Canaccord Genuity Group initiated coverage on Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating for the company. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Tilray Brands presently has an average rating of “Hold” and an average price target of $11.50.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Federal rescheduling and a consequential tax change (the effective end of 280E for qualifying medical operators) materially improves cash flow for U.S. plant-touching MSOs — a sector-wide financial catalyst that lifted cannabis stocks broadly. The Cannabis Sector’s Billion-Dollar Tax Cut
• Positive Sentiment: Tilray issued statements positioning itself for U.S. expansion and highlighted its medical and beverage businesses as growth levers — management messaging supports a longer-term bull case if U.S. opportunities materialize. Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
• Positive Sentiment: Consumer/beverage initiatives (BrewDog USA lineup) highlight diversified revenue streams beyond cannabis, which could help margins and investor perception over time. BrewDog USA Doubles Down on Headliners
• Positive Sentiment: Heavy call-option buying indicates speculative bullish interest that can amplify upside if sentiment reaccelerates. (Options flow reported April 22.)
• Neutral Sentiment: Intraday trading experienced a Limit Up/Limit Down (LULD) pause — a mechanical volatility control that signals high intraday moves but not a new fundamental development.
• Neutral Sentiment: CEO media appearances reiterate the opportunity if U.S. rules loosen, providing color but no immediate revenue impact. Tilray CEO on Possible US Cannabis Reclassification
• Negative Sentiment: “Sell-the-news” reversal and dilution overhang: the initial rally tied to Schedule III headlines faded as traders took profits, and market attention returned to an at-the-market (ATM) equity program (filed earlier in April) that could add supply pressure. Tilray sinks as Schedule III headline turns into a “sell-the-news” reversal
• Negative Sentiment: Insider selling: a director sold ~33,556 shares recently — a signal some investors interpret as caution (though timing and intent can vary). Form 4 — David G. Hopkinson Sale
• Negative Sentiment: Fundamentals still weigh: Tilray’s recent quarter missed EPS estimates and the company remains loss-making with negative margins — investors worry about funding needs and whether newfound policy tailwinds translate quickly into improved earnings for Tilray specifically.

Tilray Brands Price Performance

The stock has a market capitalization of $808.86 million, a price-to-earnings ratio of -0.51 and a beta of 2.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The company has a fifty day simple moving average of $7.03 and a two-hundred day simple moving average of $9.51.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The company had revenue of $206.73 million during the quarter, compared to analyst estimates of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same period in the prior year, the firm earned ($0.87) earnings per share. As a group, equities research analysts expect that Tilray Brands, Inc. will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tilray Brands

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLRY. Silverlake Wealth Management LLC acquired a new position in Tilray Brands in the 3rd quarter valued at $25,000. Oppenheimer & Co. Inc. bought a new position in shares of Tilray Brands in the 3rd quarter valued at $25,000. Unified Investment Management bought a new position in shares of Tilray Brands in the 3rd quarter valued at $26,000. Y Intercept Hong Kong Ltd bought a new position in shares of Tilray Brands in the 3rd quarter valued at $30,000. Finally, HighPoint Advisor Group LLC bought a new position in shares of Tilray Brands in the 3rd quarter valued at $33,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.